enGene HoldingsENGN
ENGN
About: enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
Employees: 57
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
0.71% less ownership
Funds ownership: 81.02% [Q4 2024] → 80.31% (-0.71%) [Q1 2025]
9% less funds holding
Funds holding: 34 [Q4 2024] → 31 (-3) [Q1 2025]
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
25% less funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 3 (-1) [Q1 2025]
33% less capital invested
Capital invested by funds: $275M [Q4 2024] → $183M (-$91.3M) [Q1 2025]
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$18
441%
upside
Avg. target
$18
441%
upside
High target
$18
441%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities Silvan Tuerkcan | 441%upside $18 | Market Outperform Reiterated | 29 Apr 2025 |
Financial journalist opinion
Based on 4 articles about ENGN published over the past 30 days
Neutral
Business Wire
3 days ago
enGene Reports Second Quarter 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the second quarter ended April 30, 2025, and provided a business update. “We have seen strong enrollment in the pivotal cohort of our LEGEND study,” said Ron Cooper, Chief Executive Officer of enGene. “This positions us to stay on track for our planned trial updates across all cohorts in the second.
Neutral
Business Wire
1 week ago
enGene Announces the Resignation of its Chief Medical Officer
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, announced today that Dr. Raj Pruthi resigned from his role as Chief Medical Officer on June 3, 2025. Dr. Pruthi's resignation as Chief Medical Officer will take effect on June 16, 2025. He will be supporting the organization to ensure an orderly transition of his responsibilities before he departs. The Company intends to reallocate Dr. Prut.
Neutral
Business Wire
2 weeks ago
enGene to Present at the Jefferies Global Healthcare Conference
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Jefferies Global Healthcare Conference in New York City on Wednesday, June 4, 2025, at 11:05 a.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. A.
Neutral
Business Wire
2 weeks ago
enGene Names Amy Pott as Chief Global Commercialization Officer
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced the appointment of Amy Pott as Chief Global Commercialization Officer. In this role, Ms. Pott will serve as the Company's first dedicated executive for commercialization planning and execution, reporting to enGene's Chief Executive Officer, Ron Cooper. This appointment marks a significant milestone, as the Company expects to.
Neutral
Business Wire
1 month ago
enGene to Participate in Upcoming Investor Conferences
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that management will present at upcoming investor conferences in May 2025. Details of the conferences are below: Conference: 2025 Bloom Burton & Co. Healthcare Investor Conference Date: Monday, May 5, 2025 Time: 2:30 p.m. ET Format: Corporate Presentation Conference: The Citizens Life Sciences Conference Date: Wednesday,.
Neutral
Business Wire
2 months ago
enGene Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported the grant of inducement equity awards to seven newly-hired employees, with a grant date of April 2, 2025. The inducement awards consist of a non-qualified stock options to purchase an aggregate 144,650 of the Company's common shares. The options each have an exercise price of $4.44 per share, which is equal to the closing price.
Neutral
Business Wire
2 months ago
enGene to Present at the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will present at the Stifel 2025 Virtual Targeted Oncology Forum, on Tuesday, April 8, 2025, at 4:00 p.m. ET. A live webcast of the presentation can be accessed under the “Investors” section of the enGene website at www.engene.com and will be archived there for 90 days. About enGene e.
Neutral
Business Wire
3 months ago
enGene Reports First Quarter 2025 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first quarter ended January 31, 2025, and provided a business update. “With the expansion of LEGEND study sites into Europe and Asia, enrollment in our pivotal cohort continues to track in-line with our plan to file a BLA for detalimogene in mid-2026,” said Ron Cooper, Chief Executive Officer o.
Neutral
Business Wire
3 months ago
enGene to Participate in the Leerink Partners Global Healthcare Conference
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference, taking place in Miami, FL on Tuesday, March 11, 2025, at 1:00 p.m. ET. A live webcast of the fireside chat can be accessed under the “Investors” section of the enGene website at www.engene.com a.
Positive
Seeking Alpha
3 months ago
enGene Holdings Inc.: Unknown Company Which Looks Like A Catch
enGene's DDX platform delivers genetic cargo to mucosal tissues, showing potential to transform genetic medicine beyond rare diseases, with promising preclinical and clinical data. Detalimogene voraplasmid, enGene's lead asset, shows high complete response rates in BCG-unresponsive NMIBC patients, positioning it as a viable monotherapy option. Financials reveal a market cap of $320mn and a cash runway of 14–17 quarters, indicating undervaluation compared to market potential.
Charts implemented using Lightweight Charts™